Navigation Links
Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021
Date:7/13/2011

alysis of the Market 2011-2021

5.1 SWOT Chart for the Pharmaceutical Wholesale and Distribution Market 2011-2021

5.2 Strengths

5.2.1 Large Companies Dominate the Market

5.2.2 Wholesalers Do More than Deliver Drugs

5.2.2.1 Pre-Wholesaling

5.3 Weaknesses

5.3.1 Counterfeiting

5.3.2 Low Margins

5.4 Opportunities

5.4.1 Increased Demand for Pharmaceuticals

5.4.2 Generics

5.4.3 Globalisation

5.5 Threats

5.5.1 Direct-to-Pharmacy (DTP)

5.5.1.1 DTP in Europe

5.5.1.2 The UK

5.5.1.3 Poland

5.5.1.4 DTP in Australia

5.5.1.5 Further Expansion

5.5.2 Healthcare Budget Cuts

5.5.3 Diversion and Re-importation

5.5.4 Supermarket Pharmacies

5.5.4.1 Case Study: Walmart

6. Pharmaceutical Wholesale Industry Trends 2011-2021

6.1 Combating Counterfeit Medicines

6.1.1 The US and E-Pedigree

6.1.2 European Pedigree Legislation

6.1.3 Anti-Counterfeiting Strategies in Other Markets

6.1.4 Issues in Serialisation for Wholesalers

6.2 Growth in Specialty Pharmaceuticals

6.3 Industry Consolidation

6.4 Chain Pharmacies and Vertical Integration

7. Opinions from Our Survey

7.1 Professor David Taylor, Professor of Pharmaceutical and Public Health Policy, University of London

7.1.1 The Purpose of DTP

7.1.2 The Impact of DTP on Pharmacies

7.1.3 Changes to Drug Pricing in the UK

7.1.4 DTP and the Patient

7.1.5 Wholesale Trends Across Europe

7.2 Dr Heinz Kobelt, Secretary-General, European Association of Euro-Pharmaceutical Companies (EAEPC)

7.2.1 Benefits of Parallel Trade

7.2.2 Generics and Parallel Trade

7.2.3 Parallel Traders Combating Counterfeiting

7.2.4 The DTP Model

8. Conclusions

8.1 There Will Be Steady Growth in Developed Markets
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kansas blocked the sale of ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: The Impact of ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... 3590) is complex legislation that affects virtually every ... provisions are beginning to take effect now. IVD ...
(Date:8/20/2014)... 20, 2014 Research and Markets ... "Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and ... report to their offering. A ... and geography) - Size, Share, Global Trends, Company ... and Forecast, 2013 - 2020", suggests that the ...
Breaking Medicine Technology:Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2
... 2012  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today ... 2012.  For the first quarter of 2012, the Company reported ... compared with a net income of $2.9 million, or $0.05 ... $3.8 million change in operating results is primarily due to ...
... Janssen Research & Development, LLC, (Janssen), announced today ... to the U.S. Food and Drug Administration (FDA) seeking ... an oral anticoagulant, to treat patients with deep vein ... recurrent venous thromboembolism (VTE). These submissions are ...
Cached Medicine Technology:Neurocrine Biosciences Reports First Quarter 2012 Results 2Neurocrine Biosciences Reports First Quarter 2012 Results 3Neurocrine Biosciences Reports First Quarter 2012 Results 4Neurocrine Biosciences Reports First Quarter 2012 Results 5Neurocrine Biosciences Reports First Quarter 2012 Results 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 2Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 3Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 4Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 5Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 7Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 8
(Date:8/20/2014)... Today, Zane Benefits, the #1 ... a new eBook, Affordable Care Act 101. , ... feel uncertain about how the ACA impacts their ... line. , The new eBook outlines key ACA ... their upcoming health insurance decisions. , Read the ...
(Date:8/20/2014)... Locating rates for insurance packages will now be an ... new source of term life insurance providers has been added ... 50 states at http://quotespros.com/life-insurance.html . , The database ... available for the public to find out the exact annual ... quotations that are available are good through the rest of ...
(Date:8/20/2014)... group representing U.S. obstetricians is calling for all pregnant ... the American College of Obstetricians and Gynecologists (ACOG), several ... and effectiveness of flu vaccination during pregnancy. "The ... dangerous to pregnant women, as it can cause pneumonia, ... of the college,s Immunization Expert Work Group, explained in ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, ... a group of rhesus monkeys from deadly Marburg virus, a ... 90 percent of those it infects, researchers report. The ... virus, even when it was given three days after infection, ... Science Translational Medicine . This is the first ...
(Date:8/20/2014)... Line: Less than 42 percent of women underwent ... the factors associated with foregoing reconstruction included being ... older. , Author: Monica Morrow, M.D., of the ... colleagues. , Background: The Women,s Health and Cancer ... breast reconstruction following a mastectomy. Still, most women ...
Breaking Medicine News(10 mins):Health News:Term Life Insurance Price Database Now Helps Quote Prices for Adults in 50 States Online 2Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 2Health News:Drug for Ebola-Like Virus Shows Promise in Monkeys 3Health News:Patient perspectives on breast reconstruction following mastectomy 2
... By Tobacco Advertising and Find It,Easy to Buy Cigarettes, ... against tobacco on April 2 as they join thousands ... Day, sponsored by the Campaign,for Tobacco-Free Kids. Hundreds of ... local events, go to http://www.kickbuttsday.org/events )., This ...
... March 27 The Richard B. and,Lynne V. ... John Ray have joined the Institute,s Board of ... for the Institute., "Mary Matalin,s experience in ... to the Institute as we build our organization ...
... Calif., March 27 Clarient, Inc.,(Nasdaq: CLRT ), ... the pharmaceutical industry, today announced,that it is scheduled to ... Co.,9th Annual Las Vegas Investor Conference at 4:00 p.m. ... conference is being held at the Palms,Casino Resort April ...
... Now Have Choices and Flexibility ... Typically Available on Larger Plans, NEW YORK, ... to,nine employees can now choose from a wider selection of ... larger,companies., The Guardian Life Insurance Company of America (Guardian), ...
... a mental rigidity that keeps them from folding their ... form of mental rigidity that leads to compulsive behavior ... luck even when they,re on a losing streak, a ... causes compulsive gambling, but it,s been suggested that environmental ...
... CHICAGO, IL MARCH 27, 2008 The Cardiovascular ... meta-analysis to date comparing mortality rates for drug-eluting stents ... Stent Revolution VII meeting tomorrow evening in Chicago. ... studieswas performed by a team of researchers led by ...
Cached Medicine News:Health News:D.C. Kids 'Kick Butts' on April 2 2Health News:D.C. Kids 'Kick Butts' on April 2 3Health News:Mary Matalin and John Ray Join the Cheney Cardiovascular Institute Board of Directors 2Health News:Clarient to Present at the B. Riley & Co. 9th Annual Las Vegas Investor Conference 2Health News:Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost 2Health News:Guardian Expands Dental Benefit Options Helps Small Business Owners Lower Insurance Cost 3Health News:Compulsive Gamblers Don't Learn From Their Mistakes 2Health News:Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use 2
Bone Curette, 170 mm...
Bone Currettes...
Kevorkian Endocervical Curette is a stainless-steel curette with a basket. It is narrow tipped for sampling without dilation....
...
Medicine Products: